Abstract:Somatic mutations in catalytic arginine residues of isocitrate dehydrogenases IDH1 and IDH2 occur frequently in myeloid malignancies. Heterozygous mutation of cytosolic IDH1 or mitochondrial IDH2 contributes to leukemia development by accumulating the oncometabolite (R)-2-hydroxyglutarate (R-2-HG), causing alterations of histone and DNA methylation through impaired α-ketoglutarate-dependent dioxygenases. Small molecule inhibitors ivosidenib and enasidenib, which specifically target mutant IDH1 and IDH2 respectively, are now approved for the treatment of newly diagnosed and/or relapsed/refractory acute myeloid leukemia (AML) patients with IDH1/2 mutations. However, multiple cases of therapeutic resistance to IDH inhibitors were reported. Distinct mechanisms were described for clinical resistance of IDH inhibition, such as the acquisition of secondary mutations in cis or trans on the allosteric binding site of IDH inhibitors or isoform switching. Although a few amino acid substitutions including IDH1-S280F, IDH2-Q316E and IDH2-I319M were identified to be associated with acquired resistance, the extent to which the mutational repertoire at IDH1/2 proteins and the associated mechanisms contribute to acquired resistance to IDH inhibition remains unknown. In this study, we systematically examined all potential amino acid substitution mutations on IDH1 and IDH2 by multiple orthogonal saturating mutagenesis screens in base-edited myeloid leukemia cells. We first engineered independent myeloid leukemia cell lines containing endogenous patient-derived IDH1/2 mutations by CRISPR/Cas9-mediated base-editing. We created clonal leukemia cell lines containing heterozygous IDH1-R132H (IDH1R132H/WT) or IDH2-R140Q (IDH2R140Q/WT) mutations, which are the most frequent IDH1/2 mutations in AML. The base-edited IDH1 or IDH2-mutant leukemia cells were characterized by the accumulation of the oncometabolite R-2-HG, alterations of histone and DNA methylation, and aberrant cytokine-independent cell growth. To identify all possible amino acid substitution mutations with resistance to IDH inhibition, we performed MITE-seq-based saturation variant screens, in which each amino acid was systematically substituted by all other possible amino acids, in base-edited leukemia cells. We not only validated known mutations such as IDH1-S280F, IDH2-Q316E and IDH2-I319M, but also identified a list of de novo amino acid substitutions associated with acquired resistance to IDH inhibition. Furthermore, the base-edited leukemia cells were treated continuously with ivosidenib and enasidenib up to 16 weeks to identify acquired resistance-associated IDH1/2 mutations by next-generation sequencing. Finally, we performed ultra-deep targeted sequencing of IDH1/2 genes in 11 paired diagnosis and relapsed AML samples in patients treated with ivosidenib or enasidenib as monotherapy, and identified significantly enriched IDH1/2 secondary mutations in the relapsed samples as compared to AML samples at diagnosis. Integrative analyses of multiple orthogonal mutagenesis screens uncovered a compendium of high-confidence and clinically relevant IDH1/2 mutations with resistance to IDH inhibition. Structural modelling of IDH1/2 mutation-associated protein domains provided new insights into the mechanisms for acquired resistance due to dysregulated protein 3D structure, co-factor binding, and/or steric hindrance with the binding of small molecular inhibitors. Follow-up functional studies established new IDH mutations as candidate drivers of acquired resistance to IDH inhibition through distinct mechanisms in AML. Taken together, we generated isogenic, base-edited IDH1/2 mutant myeloid leukemia cells and identified candidate amino acid substitutions conferring resistance to IDH inhibition through orthogonal saturating variant screens. We integrated the results with targeted sequencing of IDH1/2 mutations in AML patients, structural modeling, and functional studies. Our findings not only uncover de novo pathogenic mutations associated with resistance to IDH inhibition, but also provide new insights into the molecular mechanisms for acquired resistance to a targeted therapy in AML. Disclosures No relevant conflicts of interest to declare.

Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances

Evolutionary rescue model informs strategies for driving cancer cell populations to extinction

Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia

Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA

Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro

Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer

Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)

Enhanced Protein Damage Clearance Induces Broad Drug Resistance in Multitype of Cancers Revealed by an Evolution Drug‐Resistant Model and Genome‐Wide siRNA Screening

Inducible SHP-2 Activation Confers Resistance to Imatinib in Drug-Tolerant Chronic Myeloid Leukemia Cells

Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach

3089 – ELUCIDATING NEW MECHANISMS OF ACQUIRED RESISTANCE TO IDH INHIBITION BY SATURATION VARIANT SCREENING OF BASE-EDITED LEUKEMIA CELLS

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting

Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells

Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

A Combined Computational and Experimental Strategy Identifies Mutations Conferring Resistance to Drugs Targeting the BCR-ABL Fusion Protein

Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing